» Articles » PMID: 25201203

The Role of Tumor Suppressor P53 in the Antioxidant Defense and Metabolism

Overview
Journal Subcell Biochem
Publisher Springer
Specialty Biochemistry
Date 2014 Sep 10
PMID 25201203
Citations 76
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor suppressor p53 is inactivated in most cancers and the critical role of p53 in the suppression of carcinogenesis has been confirmed in many mouse models. The protein product of the tumor suppressor p53 gene works as a transcriptional regulator, activating expression of numerous genes involved in cell death, cell cycle arrest, senescence, DNA-repair and many other processes. In spite of the multiple efforts to characterize the functions of p53, the mechanisms of tumor suppression by p53 are still elusive. Recently, new activities of p53 such as regulation of reactive oxygen species (ROS) and metabolism have been described and the p53-regulated genes responsible for these functions have been identified. Metabolic derangements and accumulation of ROS are features of carcinogenesis, supporting the idea that many tumor suppressive effects of p53 can be mediated by regulation of metabolism and/or ROS. Mutations in the p53 gene can not only inactivate wild type function of p53 but also endow p53 with new functions such as activation of new metabolic pathways contributing to carcinogenesis. Understanding the metabolic and antioxidant functions of p53 allows us to develop approaches to restore p53 function in cancers, where p53 is inactivated, in other to ensure the best outcome of anti-cancer treatment.

Citing Articles

Exploiting somatic oncogenic driver alterations in a patient with Li-Fraumeni syndrome- paving the path towards precision medicine: a case report.

Seeling C, Dahlum S, Marienfeld R, Jan V, Rack B, Gerstenmaier U J Cancer Res Clin Oncol. 2025; 151(1):37.

PMID: 39820556 PMC: 11739273. DOI: 10.1007/s00432-024-06077-7.


Chronic kidney disease and aging: dissecting the p53/p21 pathway as a therapeutic target.

Goyal K, Afzal M, Altamimi A, Babu M, Ballal S, Kaur I Biogerontology. 2024; 26(1):32.

PMID: 39725742 DOI: 10.1007/s10522-024-10173-z.


Enhancing Gpx1 palmitoylation to inhibit angiogenesis by targeting PPT1.

Ma Y, Yuan X, Wei A, Li X, Patar A, Su S Redox Biol. 2024; 77:103376.

PMID: 39423458 PMC: 11532489. DOI: 10.1016/j.redox.2024.103376.


8-Week Extract Administration Improves Submaximal Exercise Capacity in Mice by Enhancing Skeletal Muscle Antioxidant Gene Expression and Plasma Antioxidant Capacity.

Huang J, Tong Y, Wang S, Tagawa T, Seki Y, Ma S Antioxidants (Basel). 2024; 13(9).

PMID: 39334806 PMC: 11428225. DOI: 10.3390/antiox13091147.


Assessment of the Circulating PD-1 and PD-L1 Levels and P53 Expression as a Predictor of Relapse in Pediatric Patients with Wilms Tumor and Hypernephroma.

Sahyon H, Alharbi N, Asad Z, El Shishtawy M, Derbala S Children (Basel). 2024; 11(9).

PMID: 39334568 PMC: 11430274. DOI: 10.3390/children11091035.


References
1.
Levine A . p53, the cellular gatekeeper for growth and division. Cell. 1997; 88(3):323-31. DOI: 10.1016/s0092-8674(00)81871-1. View

2.
Italiano D, Lena A, Melino G, Candi E . Identification of NCF2/p67phox as a novel p53 target gene. Cell Cycle. 2012; 11(24):4589-96. PMC: 3562304. DOI: 10.4161/cc.22853. View

3.
Crighton D, Wilkinson S, OPrey J, Syed N, Smith P, Harrison P . DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell. 2006; 126(1):121-34. DOI: 10.1016/j.cell.2006.05.034. View

4.
Matheu A, Maraver A, Klatt P, Flores I, Garcia-Cao I, Borras C . Delayed ageing through damage protection by the Arf/p53 pathway. Nature. 2007; 448(7151):375-9. DOI: 10.1038/nature05949. View

5.
Reliene R, Fischer E, Schiestl R . Effect of N-acetyl cysteine on oxidative DNA damage and the frequency of DNA deletions in atm-deficient mice. Cancer Res. 2004; 64(15):5148-53. DOI: 10.1158/0008-5472.CAN-04-0442. View